Literature DB >> 25912521

Drug-induced liver injury: Interactions between drug properties and host factors.

Minjun Chen1, Ayako Suzuki2, Jürgen Borlak3, Raúl J Andrade4, M Isabel Lucena5.   

Abstract

Idiosyncratic drug-induced liver injury (DILI) is a common cause for drug withdrawal from the market and although infrequent, DILI can result in serious clinical outcomes including acute liver failure and the need for liver transplantation. Eliminating the iatrogenic "harm" caused by a therapeutic intent is a priority in patient care. However, identifying culprit drugs and individuals at risk for DILI remains challenging. Apart from genetic factors predisposing individuals at risk, the role of the drugs' physicochemical and toxicological properties and their interactions with host and environmental factors need to be considered. The influence of these factors on mechanisms involved in DILI is multi-layered. In this review, we summarize current knowledge on 1) drug properties associated with hepatotoxicity, 2) host factors considered to modify an individuals' risk for DILI and clinical phenotypes, and 3) drug-host interactions. We aim at clarifying knowledge gaps needed to be filled in as to improve risk stratification in patient care. We therefore broadly discuss relevant areas of future research. Emerging insight will stimulate new investigational approaches to facilitate the discovery of clinical DILI risk modifiers in the context of disease complexity and associated interactions with drug properties, and hence will be able to move towards safety personalized medicine.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical toxicology; Drug clearance; Drug metabolism; Drug physicochemical properties; Drug-host Interaction; Drug-induced liver injury; Host factors; Pharmacogenetics

Mesh:

Year:  2015        PMID: 25912521     DOI: 10.1016/j.jhep.2015.04.016

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  89 in total

1.  Evaluation of DILI Predictive Hypotheses in Early Drug Development.

Authors:  Rosa Chan; Leslie Z Benet
Journal:  Chem Res Toxicol       Date:  2017-03-15       Impact factor: 3.739

Review 2.  Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.

Authors:  Emanuel Raschi; Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2019-10-24       Impact factor: 5.810

3.  The Opportunities of Metabolomics in Drug Safety Evaluation.

Authors:  Pengcheng Wang; Amina I Shehu; Xiaochao Ma
Journal:  Curr Pharmacol Rep       Date:  2017-01-03

4.  Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI).

Authors:  Eni Minerali; Daniel H Foil; Kimberley M Zorn; Thomas R Lane; Sean Ekins
Journal:  Mol Pharm       Date:  2020-06-08       Impact factor: 4.939

5.  Predicting fatalities in serious idiosyncratic drug-induced liver injury-a matter of choosing the best Hy's law.

Authors:  Fernando Bessone
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-18

6.  The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury.

Authors:  Saravanakumar Selvaraj; Jung-Hwa Oh; Reinhard Spanel; Florian Länger; Hyoung-Yun Han; Eun-Hee Lee; Seokjoo Yoon; Jürgen Borlak
Journal:  Oncotarget       Date:  2017-09-23

7.  Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations.

Authors:  Dolly A Parasrampuria; Leslie Z Benet; Amarnath Sharma
Journal:  AAPS J       Date:  2018-03-13       Impact factor: 4.009

8.  Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone.

Authors:  Jun-Hong Ye; Yunn-Fang Ho; Angela W-F On; Wen-Wen Chen; Yen-Ming Huang; Wei-I Huang; Yun-Wen Tang
Journal:  Int J Clin Pharm       Date:  2018-07-26

9.  Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study.

Authors:  Qin Sun; Hai-Peng Liu; Rui-Juan Zheng; Peng Wang; Zhi-Bin Liu; Wei Sha; He-Ping Xiao
Journal:  Clin Drug Investig       Date:  2017-12       Impact factor: 2.859

Review 10.  Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.

Authors:  Mahmoud Slim; Inmaculada Medina-Caliz; Andres Gonzalez-Jimenez; M Rosario Cabello; Fermin Mayoral-Cleries; M Isabel Lucena; Raul J Andrade
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.